by Kall Kwik WGC | Nov 14, 2017 | Free Library
November, 2017 SMM-170 The Great Schism While recent approval by the FDA of Novartis’ new Kymriah gene therapy for leukaemia is undoubtedly cause for celebration, evolution suggests that such technological advance might also be the herald of...
by Kall Kwik WGC | Nov 1, 2017 | Free Library
October, 2017 SMM-168 Breathing Data Amidst announcements and industry gossip about how companies such as Apple and Google are planning to upend the life science industry by their use of data, Novartis’s new CEO designate, Vas Narasimham,...
by Kall Kwik WGC | Nov 1, 2017 | Free Library
October, 2017 SMM-169 Pharma’s Coral Reef A comparison of the life science industry past and present reveals that holobionts are now the principal form of competitor, while the fully integrated, self-sufficient company is becoming a...
by Kall Kwik WGC | Oct 17, 2017 | Free Library
October, 2017 SMM-167 Life Lessons Generics were once an unstoppable behemoth, threatening to dominate the industry as they sucked up market share. But their model seems to be fading. In this low-cost, non-innovative habitat, existing giants are...
by Kall Kwik WGC | Sep 1, 2017 | Free Library
September, 2017 SMM-166 Life Story Product Life Cycle (PLC) is a familiar tool to experienced executives in pharma or medtech. It’s often assumed to be synonymous with line extension tactics, for defending against me-toos and generics. But the...
